In B16 melanoma models subjected to radiotherapy and tumor antigen exposure, subsequent anti-CTLA-4 treatment markedly improved tumor clearance, whereas STING-deficient tumors exhibited reduced responsiveness and diminished CD8+ T cell infiltration [92]. This evidence concerns the gene CTLA4 and melanoma.